

Dear Colleague,

August 4, 2015

The broad spectrum fluoroquinolone antibiotics (FQs) are some of the most potent oral antibiotics in clinical use today. They are among the most often prescribed antimicrobial agents.¹⁰⁴ Initially they were recommended as drugs of last resort. FQs act by inhibiting bacterial DNA gyrase and topoisomerase IV. By doing so they are bacteriolytic instead of bacteriostatic.

In this letter I would like to give you additional information regarding the adverse effects (AEs) to FQs, which appear to happen with greater frequency and chronicity than previously known.⁷⁸ The adverse effects of FQs are multi-systemic in nature, co-occurring and therefore meeting the qualifications for a Syndrome: the Fluoroquinolone Toxicity Syndrome (FTS).^{76,77,78}

AEs to FQs can be either immediate or delayed.^{1,6} They also can become permanent in nature.²⁵ Tendonitis/tendinosis, gastrointestinal (nausea, diarrhea) and central nervous system AEs (headache, dizziness) are most common.

The pathophysiology of the AEs to FQs are multifaceted: Inhibition to and/or disruption of the GABA receptor; Chelation of divalent ions such as magnesium with disruption of cellular function; Oxidative stress; Harm to nuclear DNA, harm to mitochondria and other cell organelles such as lysosomes; Depletion of mitochondrial DNA; Direct toxicity; From a recent Mayo Clinic article; ⁸²Iron chelation leading to epigenetic effects through inhibition of dioxygenases, inducing global epigenetic changes and inhibition of collagen maturation leading to tendinopathy and liver injury.

A summary of possible adverse effects:

1. Fluoroquinolones may harm not only Achilles tendons, but also other tendons, ligaments, connective tissue, cartilage, bones and muscles.^{1-9, 98-103}
2. Fluoroquinolones may induce apoptosis of human body cells and thereby harm their mitochondria by several mechanisms including oxidative stress.²⁹⁻³⁷
3. Fluoroquinolones may harm human DNA and may therefore be genotoxic.³⁸⁻⁴⁹
4. Fluoroquinolones have been used as chemotherapy or as an adjunct to existing chemotherapy because of their apoptotic properties.⁵⁰⁻⁶⁵
5. Fluoroquinolones may harm the Central Nervous System,¹⁸⁻²⁸ the Peripheral Nervous System¹⁰⁻¹⁷ as well as many other endocrine and non-endocrine organs.⁸³⁻⁹⁷
6. Fluoroquinolones appear to be able to either induce or worsen an existing autoimmune diseases as well as give rise to an immune-allergic mediated reaction.⁶⁶⁻⁷⁵

Patients may present with a wide array of symptoms: *Joints: pain, swelling, redness, fluid. Cartilage damage. Meniscus tears. Tendons: Pain, tears, rupture, swelling. Ligament damage. Muscles: pain, weakness and wasting, involuntary muscle contraction, twitching or jerks. Weight loss, nausea, diarrhea, hair loss, visual abnormalities, severe fatigue, exertion inability, headache, feelings of head pressure, dizziness, tremors, insomnia or sleep disturbance, hallucinations, convulsions, anxiety, psychosis. neuropathy pain, tingling, prickling, burning, "shocks," buzzing, squeezing, or "pressure" in the arms, legs, body, or head, paresthesia, blood pressure changes, autonomic neuropathy and sensory disturbance, inability to sweat, excessive sweating, loss of bladder control, orthostatic hypotension, tinnitus, dizziness, lightheadedness, fainting. Hypersensitivity to pain or to light touch. Insomnia. Disturbance of glucose regulation, signs of hypo or hyperglycemia. Elevated liver enzymes, liver failure, kidney damage or failure. Heart: irregular heart beat with palpitations, QT prolongation, torsade de point. Vision disturbance like floaters. Difficulty walking, difficulty talking, difficulty swallowing, difficulty thinking.*^{76,108}

Acknowledgment of these often complex AEs is important for the patient. If AEs to FQs are not viewed as inter-related, it is easy to miss the diagnosis of FTS. Patients are then diagnosed as having fibromyalgia, somatoform or other psychiatric illness because doctors who are unaware of the potential severity and duration of some fluoroquinolone AEs. Of course It is also important to exclude other pathology that was either provoked by or already existing but only become apparent after the use of fluoroquinolone antibiotics.

It is my hope that many patients will benefit as medical professionals become more aware of the information in this letter. Thank you for your time and consideration.

Respectfully yours,

Miriam J. de Jonge M.D.

Contact Email: fqdeardocor@gmail.com

Postscript and Accountability. To write this letter I have done a PUB Med and Google scholar search for fluoroquinolones and the several adverse events. I tried to refer to human research only as much as possible, although animal studies may provide valuable data. I also tried to use recent publications except when I thought older ones to be of importance.

Being harmed myself by the adverse events to these antibiotics, I wanted to find out for myself what could be the explanation for my ongoing symptoms.

I also wanted to update the last “Dear Doctor” letter that was written in 2006 by yet another physician who was harmed after the use of Fluoroquinolones Antibiotics.¹⁰⁷

As you might know medical literature post marketing has a tendency to emphasize a more favorable outcome than is the reality^{105,106} Lately two citizens petitions for two more black box warnings were submitted to the FDA by professor Charles Bennet from SONAR : one for psychiatric EAs.⁸² And one for Mitochondrial damage.⁸¹

Tendons, muscles and bones:

1. Lewis T, Cook J. Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature.

Journal of Athletic Training. 2014 May-Jun;49(3):422-7.

<http://www.ncbi.nlm.nih.gov/pubmed/24762232>

2. Tsai WC, Hsu CC., et al. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen.

J Orthop Res. 2011 Jan;29(1):67-73.

<http://www.ncbi.nlm.nih.gov/pubmed/20602464>

3. Kaleagasioglu F, Olcay E. Fluoroquinolone-Induced Tendinopathy: Etiology and Preventive Measures. Tohoku J Exp Med. 2012;226(4):251-8.

[http://www.ncbi.nlm.nih.gov/pubmed/?term=Fluoroquinolone-](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fluoroquinolone-Induced+Tendinopathy%3A+Etiology+and+Preventive+Measures+2012)

[Induced+Tendinopathy%3A+Etiology+and+Preventive+Measures+2012](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fluoroquinolone-Induced+Tendinopathy%3A+Etiology+and+Preventive+Measures+2012)

4. Finnoff JT, Smith J., et al. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PM R. 2011 Feb;3(2):132-42. Department of Physical Medicine and Rehabilitation, Mayo Clinic College of Medicine, Mayo Clinic Sports Medicine Center, Rochester, MN 55905, USA.

<http://www.levaquinadversesideeffect.com/wp-content/uploads/Documents/Hall-2011.pdf>

5. Eisele S, Garbe E. et al. **Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature.** Int J Clin Pharmacol Ther. 2009 Mar;47(3):165-8.
<http://www.ncbi.nlm.nih.gov/pubmed/19281725>
6. Sendzik J, Lode H., et al. **Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data.** Int J Antimicrob Agents. 2009 Mar;33(3):194-200.
<http://www.sciencedirect.com/science/article/pii/S0924857908003531>
7. Maurin N. **Fluoroquinolone-induced Achilles tendon rupture** Dtsch Med Wochenschr. 2008 Feb;133(6):241-4
<http://www.ncbi.nlm.nih.gov/pubmed/18236349>
8. Sendzik J, Shakibaei M., et al., **Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells.** Toxicology. 2005 Aug 15;212(1):24-36.
<http://www.ncbi.nlm.nih.gov/pubmed/15890441>
9. O-Lee T, Stewart CE., et al., **Fluoroquinolone-induced arthralgia and myalgia in the treatment of sinusitis.** Am J Rhinol. 2005 Jul-Aug;19(4):395-9.
<http://www.ncbi.nlm.nih.gov/pubmed/16171175>

Peripheral Neuropathy:

10. Jacquelyn K. Francis, Elizabeth Higgins. **Permanent Peripheral Neuropathy: A Case Report on a Rare but Serious Debilitating Side-Effect of Fluoroquinolone Administration.** Journal of Investigative Medicine High Impact Case Reports July-September 2014 vol. 2 no. 3
<http://hic.sagepub.com/content/2/3/2324709614545225.full>
11. Etminan M, Brophy JM, Samii., et al. **Oral fluoroquinolone use and risk of peripheral neuropathy. A pharmacoepidemiologic study.** Neurology Today: 2 October 2014 - Volume 14 - Issue 19 - p 41-44
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Oral+fluoroquinolone+use+and+risk+of+peripheral+neuropathy.+A+pharmacoepidemiologic+study.>
12. Jumma OK, Dick J., et al. **Ciprofloxacin induced acute small fibre neuropathy. Case report.** Can J Neurol Sci. 2013 Jan;40(1):127-8
<http://www.ncbi.nlm.nih.gov/pubmed/23427360>

13. Ali AK. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol. 2015 Jun 19. pii: S1047-2797(15)00224-0.
<http://www.ncbi.nlm.nih.gov/pubmed/24472364>

14. Pharmacovigilance Review FDA :Internal Report on possible permanent PeripheralNeuropathy by Fluoroquinolones. Apr. 2013.
https://drive.google.com/file/d/0B093-_bthq2Db1c1cFlmd1hvRGM/view?usp=sharing

15. Panas M, Karadima G., et al. Hereditary Neuropathy Unmasked by Levofloxacin 2011. Ann Pharmacother. 2011 Oct;45(10):1312-3.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Hereditary+Neuropathy+Unmasked+by+Levofloxacin>

16. Liang VY, Ghearing GR., et al. Carpal tunnel syndrome after ciprofloxacin-induced tendinitis. J Clin Neuromuscul Dis. 2010 Mar;11(3):165-6.
<http://www.ncbi.nlm.nih.gov/pubmed/20215992>

17. Cohen JS. Peripheral neuropathy associated with fluoroquinolones. Ann Pharmacother. 2001 Dec;35(12):1540-7.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Cohen+Peripheral+Neuropathy+associated+with+fluoroquinolones>

CNS:

18. Wang JM, Zahedi S.A possible case of levofloxacin-associated amnesia, depression, and paresthesia. Conn Med. 2014 Apr;78(4):229-30.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=a+possible+case+of+levofloxacin+associated+amnesia+depression+and+paresthesia>
<http://connmed.csms.org/i/284691-apr-2014/38>

19. Anthony J. Busti, M.D., Pharm.D., et al.What is the mechanism by which the fluoroquinolone can increase a patients for developing a seizure or worse epilepsy.Pharmacology Weekly. 2014
<http://www.pharmacologyweekly.com/articles/fluoroquinolone-antibiotic-seizures-epilepsy-CNS-ciprofloxacin-levofloxacin-moxifloxacin-gemifloxacin>

20. Vikas Raj, Lt Cola., et al. Levofloxacin induced delirium with psychotic features in a young patient. Med J Armed Forces India. 2013 Oct;69(4):404-5.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=Levofloxacin+induced+delirium+with+psychotic+features+in+a+young+patient>

21. Chauhan U, Shanbag P., et al. **Ofloxacin-induced hallucinations**. Indian J Pharmacol. 2013 Mar-Apr; 45(2): 189–190.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Ofloxacin-induced+hallucinations>

22. Mittal SO, Machado DG., et al. **Orofacial dyskinesia after moxifloxacin treatment--a case with normal hepatorenal function and review of literature**. Clin Neuropharmacol. 2012 Nov-Dec;35(6):292-4.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Orofacial+dyskinesia+after+moxifloxacin+treatment--a+case+with+normal+hepatorenal+function+and+review+of+literature>

23. Arunkandasamy, D Srinath **Levofloxacin-induced acute anxiety and insomnia**. Journal of Neuroscience in Rural Practice. 2012 May;3(2):212-4.
<http://www.ncbi.nlm.nih.gov/pubmed/22865986>

24. Tomé AM, Filipe A. **Quinolones: review of psychiatric and neurological adverse reactions**. Drug Saf. 2011 Jun 1;34(6):465-88.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Quinolones%3A+review+of+psychiatric+and+neurological+adverse+reactions.+Tom%C3%A9+AM1%2C+Filipe+A>

25. Kiangkitiwan B, Doppalapudi A., et al. **Levofloxacin-induced delirium with psychotic features**. Gen Hosp Psychiatry. 2008 Jul-Aug;30(4):381-3.
<http://www.ncbi.nlm.nih.gov/pubmed/18585545/>

26. Cheung YF, Wong WW., et al. **Ciprofloxacin Induced Palatal Tremor Palatal tremor, characterized by rhythmic contractions of the soft palate**. Mov Disord. 2007 May 15;22(7):1038-43.
<http://www.ncbi.nlm.nih.gov/pubmed/17357133>

27. Ajay Tripathi, MS, FRCS(Ed)., et al. **Acute Psychosis Following the Use of Topical Ciprofloxacin**. JAMA Ophthalmol. 2002;120(5):665-666.
<http://archophth.jamanetwork.com/article.aspx?articleid=270419>

28. Green MA, Halliwell RF. **Selective antagonism of the GABA(A) receptor by ciprofloxacin and biphenylacetic acid**. Br J Pharmacol. 1997 Oct;122(3):584-90.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Selective+antagonism+of+the+GABAA+receptor+by+ciprofloxacin+and+biphenylacetic+acid>

Mitochondrial damage + Oxidative stress:

- 29.** Ghaly H, Jörns A2., et al. **Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells.** Eur J Pharm Sci. 2014 Feb 14;52:206-14.
<http://www.ncbi.nlm.nih.gov/pubmed/24284031>
- 30.** Sameer Kalghatgi, Catherine S., et al. **Bactericidal Antibiotics Induce Mitochondrial Dysfunction and Oxidative Damage in Mammalian Cells.** Science Translational Medicine. 2013 Jul 3;5(192):192ra85.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760005/>
- 31. A Pharmacovigilance Review FDA Internal Report.** April 17, 2013: § 8.6
<https://drive.google.com/file/d/0BzLMHZg5q0Y3VkVJUmxSIQtbWs/edit>
- 32.** Barnhill AE, Brewer MT., et al. **Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components.** Antimicrob Agents Chemother. 2012 Aug;56(8):4046-51.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421593/>
- 33.** Li HT, Zhu SY., et al. **The effect of moxifloxacin on apoptosis of airway smooth muscle cells and mitochondria membrane potential.** ZhonghuaJie He He Hu Xi ZaZhi. 2011 Sep;34(9):684-7
<http://www.ncbi.nlm.nih.gov/pubmed/22177495>
- 34.** V Talla and PR Veerareddy. **Oxidative Stress Induced by Fluoroquinolones on Treatment for Complicated Urinary Tract Infections in Indian Patients.** J Young Pharm. 2011 Oct-Dec; 3(4): 304–309.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249743/?report=printable>
- 35.** Hsiao CJ, Younis H., et al. **Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction.** Chemico-Biological Interactions. 2010 Oct 6;188(1):204-13
<http://www.ncbi.nlm.nih.gov/pubmed/20655887>
- 36.** Lowes DA, Wallace C., et al. **The mitochondria targeted antioxidant MitoQ protects against fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human Achilles tendon cells.** Free Radic Research. 2009 Apr;43(4):323-8.
<http://www.ncbi.nlm.nih.gov/m/pubmed/19235604/>
- 37.** Boya P, Andreau K., et al. **Lysosomal Membrane Permeabilization Induces Cell Death in a Mitochondrion-dependent Fashion.** The Journal of Experimental Medicine. 2003 May 19;197(10):1323-34
<http://jem.rupress.org/content/197/10/1323.full>

DNA damage and genotoxicity:

- 38.** de Guidi G, Bracchitta G., et al. **Photosensitization Reactions of Fluoroquinolones and Their Biological Consequences.** PhotochemPhotobiol. 2011 Nov-Dec;87(6):1214-29.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Photosensitization+Reactions+of+Fluoroquinolones+and+Their+Biological+Consequences>
- 39.** Koziel R, Szczepanowska J., et al. **Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells.** J Physiol Pharmacol. 2010 Apr;61(2):233-9.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=.+CIPROFLOXACIN+INHIBITS+PROLIFERATION+AND+PROMOTES+GENERATION+OF+ANEUPLOIDY+IN+JURKAT+CELLS>
- 40.** Pommier Y, Leo E., et al. **DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs.** Chemistry and Biology. Volume 17, Issue 5, p421–433, 28 May 2010
<http://www.sciencedirect.com/science/article/pii/S1074552110001614>
- 41.** Sánchez G, Hidalgo ME., et al. **Induced and photoinduced DNA damage by quinolones: ciprofloxacin, ofloxacin and nalidixic acid determined by comet assay.** PhotochemPhotobiol. 2005 Jul-Aug;81(4):819-22.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Induced+and+photoinduced+DNA+damage+by+quinolones%3A+ciprofloxacin%2C+ofloxacin+and+nalidixic+acid+determined+by+comet+assay>
- 42.** Viola G, Facciolo L., et al. **Photophysical and Phototoxic Properties of the Antibacterial Fluoroquinolones Levofloxacin and Moxifloxacin.** ChemBiodivers. 2004 May;1(5):782-801.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Photophysical+and+Phototoxic+Properties+of+the+Antibacterial+Fluoroquinolones+Levofloxacin+and+Moxifloxacin>
- 43.** Zhang T, Li JL., et al. **Compare two methods of measuring DNA damage induced by photogenotoxicity of fluoroquinolones.** Acta Pharmacol Sin. 2004 Feb;25(2):171-5.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Compare+two+methods+of+measuring+DNA+damage+induced+by+photogenotoxicity+of+fluoroquinolones>
- 44.** Laurent Marrot, Jean Phillippe Belaïdi., et al. **Molecular Responses to Photogenotoxic Stress Induced by the Antibiotic Lomefloxacin in Human**

Skin Cells: From DNA Damage to Apoptosis.Journal of Investigative Dermatology 2003 Sep;121(3):596-606.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Journal+of+Investigative+Dermatology+%282003%29+121%2C+596%E2%80%93606%3B+doi%3A10.1046%2Fj.1523-1747.2003.12422.x>

45.Hiraku Y, Kawanishi S.,**Distinct mechanisms of guanine-specific DNA photodamage induced by nalidixic acid and fluoroquinolone antibacterials.** Arch BiochemBiophys. 2000 Oct 15;382(2):211-8.
<http://www.ncbi.nlm.nih.gov/pubmed/11068871>

46.Hamanaka H, Mizutani., et al.**Melanocyte melanin augments sparfloxacin-induced phototoxicity.**Journal of Dermatological Science. 1999 Sep;21(1):27-33.
<http://www.jdsjournal.com/article/S0923-1811%2899%2900010-9/abstract>

47.Mäkinen M, Forbes PD., et al. **Quinolone antibacterials: a new class of photochemical carcinogens.** J PhotochemPhotobiol B. 1997 Feb;37(3):182-7
<http://www.ncbi.nlm.nih.gov/pubmed/9085565>

48. Lawrence JW, Claire DC.,et al.**Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.**Mol Pharmacol. 1996 Nov;50(5):1178-88.
<http://m.molpharm.aspetjournals.org/content/50/5/1178.abstract>

49.Mukherjee A, Sen S., et al. **Ciprofloxacin: mammalian DNA topoisomerase type II poison in vivo.** MutatRes. 1993 Feb;301(2):87-92.
<http://www.ncbi.nlm.nih.gov/pubmed/7678175?dopt=full>

Use as Chemotherapy:

50. Kljun J, Bratsos I., et al. **New uses for old drugs: attempts to convert quinolone antibacterials into potential anticancer agents containing ruthenium.** Inorg Chem. 2013 Aug 5;52(15):9039-52.
<http://www.ncbi.nlm.nih.gov/pubmed/23886077>

51. Tomasz Kloskowski Natalia Gurtowska., et al. **Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.** International Journal of Oncology 2012 Dec;41(6):1943-9
<http://www.ncbi.nlm.nih.gov/pubmed/23042104>

52. Hawtin RE, Stockett DE., et al. **Voreloxin Is an Anticancer Quinolone Derivative that Intercalates DNA and Poisons Topoisomerase II.**PLoS One. 2010 Apr 15;5(4):e10186.

<http://www.ncbi.nlm.nih.gov/pubmed/20419121>

53 Daniel J. Smart, H. D., et al. **Ciprofloxacin-induced G2 arrest and apoptosis in TK6 lymphoblastoid cells is not dependent on DNA double-strand break formation.** *Cancer Biol Ther.* 2008 Jan; 7(1): 113–119.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579770/>

54. Mondal ER, Das SK., et al. **Comparative evaluation of antiproliferative activity and induction of apoptosis by some Fluoroquinolones with a human non-small cell lung cancer line in culture.** *Asian Pacific Journal of Cancer Prevention.* 2004 Apr-Jun;5(2):196-204.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Comparative+evaluation+of+antiproliferative+activity+and+induction+of+apoptosis+by+some+Fluoroquinolones+with+a+human+non-small+cell+lung+cancer+line+in+culture>

55. Kamat AM, Lamm DL., **Antitumor activity of common antibiotics against superficial bladder cancer.** *Urology.* 2004 Mar;63(3):457-60.
<http://www.ncbi.nlm.nih.gov/pubmed/15028437>

56. Sissi C, Palumbo M., **The quinolone family: from antibacterial to anticancer agents.** *Current Medicinal Chemistry Anticancer Agents.* 2003 Nov;3(6):439-50.
<http://www.ncbi.nlm.nih.gov/pubmed/14529452>

57. C Herold, M Ocker., et al. **Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells.** *British Journal of Cancer.* 2002 Feb 1; 86(3): 443–448
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375221/>

58. Edward J. Fox, MD, Jesse T. Torbert., et al. **The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma.** *Community Oncology* November/December 2000
<http://www.oncologypractice.com/co/journal/articles/0206516.pdf>

59. Kamat AM, DeHaven JL., et al. **Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer.** *Urology.* 1999 Jul;54(1):56-61.
<http://www.ncbi.nlm.nih.gov/pubmed/10414727>

60. Xia Y, Yang ZY., et al. **Recent advances in the Discovery and Development of quinolones and analoges as antitumor agent.** *Current Medicinal Chemistry.* 1999 Mar;6(3):179-94.
<http://www.ncbi.nlm.nih.gov/pubmed/10219099>

- 61.** Yamakuchi M, Nakata M., et al. **New quinolones, ofloxacin and levofloxacin, inhibit telomerase activity in transitional cell carcinoma cell lines.** *Cancer Lett.* 1997 Nov 11;119(2):213-9.
<http://www.ncbi.nlm.nih.gov/pubmed/9570374?dopt=Abstract>
- 62.** Elsea SH, Westergaard M., et al. **Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.** *Biochemistry.* 1997 Mar 11;36(10):2919-24.
<http://www.ncbi.nlm.nih.gov/pubmed/9062121?dopt=Abstract>
- 63.** Mäkinen M, Forbes PD., et al. **Quinolone antibacterials: a new class of photochemical carcinogens.** *J Photochem Photobiol B.* 1997 Feb;37(3):182-7
<http://www.ncbi.nlm.nih.gov/pubmed/9085565>
- 64.** Lawrence JW, Claire DC., et al. **Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.** *Mol Pharmacol.* 1996 Nov;50(5):1178-88.
<http://m.molpharm.aspetjournals.org/content/50/5/1178.abstract>
- 65.** Gootz TD, Barrett JF., et al. **Inhibitory effects of quinolone antibacterial agents on eukaryotic topoisomerases and related test systems.** *Antimicrobial agents and chemotherapy.* 1990 Jan;34(1):8-12.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Inhibitory+effects+of+quinolone+antibacterial+agents+on+eucaryotic+topoisomerases+and+related+test+systems>.

Autoimmunedisease/immunoallergic-allergicreaction:

- 66.** García Juárez I, Miquel R., et al. **Levofloxacin-induced autoimmune hepatitis. Description of a case.** *Gastroenterol Hepatol.* 2014 Jan;37(1):46-8.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=\[Levofloxacin-induced+autoimmune+hepatitis.+Description+of+a+case\]](http://www.ncbi.nlm.nih.gov/pubmed/?term=[Levofloxacin-induced+autoimmune+hepatitis.+Description+of+a+case])
- 67.** Wang SH, Xie YC., et al. **Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases.** *Zhonghua Yi Xue Za Zhi* 2013 May 7;93(17):1283-6.
[http://www.ncbi.nlm.nih.gov/pubmed/?term=\[Fluoroquinolone+associated+myasthenia+gravis+exacerbation%3A+clinical+analysis+of+9+cases\]](http://www.ncbi.nlm.nih.gov/pubmed/?term=[Fluoroquinolone+associated+myasthenia+gravis+exacerbation%3A+clinical+analysis+of+9+cases]).
- 68.** Dana M. Blyth, Elizabeth Markelz., et al. **Cutaneous leukocytoclastic vasculitis associated with levofloxacin therapy.** *Infect Dis Rep.* 2012 Jan 2; 4(1): e11.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892663/>

- 69.** Anty R, Hastier P., et al. **Unusual evolution of ciprofloxacin-induced hepatitis revealing a possible link with IgG4-associated autoimmune hepatitis.** Digestive and Liver Disease. 2011 Nov;43(11):922-3.
<http://www.ncbi.nlm.nih.gov/pubmed/21752734>
- 70.** Garbe E, Andersohn F., et al. **Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.** Br J Haematol. 2011 Sep;154(5):644-53.
<http://www.ncbi.nlm.nih.gov/pubmed/21749359>
- 71.** Jones SC, Sorbello A., et al. **Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.** Drug Safety. 2011 Oct 1;34(10):839-47. FDA.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Fluoroquinolone-associated+myasthenia+gravis+exacerbation%3A+evaluation+of+postmarketing+reports+from+the+US+FDA+adverse+event+reporting+system+and+a+literature+review>
- 72.** van den Berg FP, Wagenvoort JH., et al. **Ciprofloxacin-induced hemorrhagic vasculitis.** Ann Vasc Surg. 2010 Feb;24(2):256.e13-5.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Ciprofloxacin-induced+hemorrhagic+vasculitis.+van+den+Berg>
- 73.** Tuccori M, Guidi B et al. **Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.** Platelets. 2008 Aug;19(5):384-7.
<http://www.ncbi.nlm.nih.gov/pubmed/18791946>
- 74.** Lim S, Alam MG. **Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.** Ren Fail. 2003 Jul;25(4):647-51.
<http://www.ncbi.nlm.nih.gov/pubmed/12911170>

75. Vergne P, Bertin P., et al. **Drug-induced rheumatic disorders: incidence, prevention and management.** Drug Saf. 2000 Oct;23(4):279-93
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Drug-induced+rheumatic+disorders%3A+incidence%2C+prevention+and+management>.

Divers/Research:

76. The UCSD Fluoroquinolone Effects Study.
Professor Beatrice A. Golomb, the University of California, San Diego.
http://www.fqstudy.info/Fluoroquinolone_Effects_Study/Study_Information.html
http://www.fqstudy.info/Fluoroquinolone_Effects_Study/About_Dr._Golomb.html

77. Megan Strauchman and Mark W. Morningstar., et al. **Fluoroquinolone toxicity symptoms in a patient presenting with low back pain.**ClinPract. 2012 Oct 12; 2(4): e87.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981197/>

78. Cohen. Jay S. **Fluoroquinolone Toxicity Syndrome: a letter to the senate committee on Health, Education & Labor.**

<http://www.medicationsense.com/articles/2014/letter.php>

79. Cohen. Jay S. **An Open Letter To Congressman Holt on Severe, Disabling Reactions Linked to Cipro, Levaquin, and Other Fluoroquinolone Antibiotics**

http://medicationsense.com/articles/jan_mar_04/congress_ltr.php

80. Bennet C. **Citizen petition to FDA for psychiatric side effects.**

University of South Carolina. Southern Network on adverse Reactions. SONAR. September 8, 2014.

https://drive.google.com/file/d/0B093-_bthq2DOTVTQmdBYXYzZ0k/view?usp=sharing

81. Bennet, C. **Citizen petition to FDA for mitochondrial warning.**

University of South Carolina. SONAR. June 18, 2014.

https://drive.google.com/file/d/0B093-_bthq2DUDZIV0tCV2ZjWk0/view?usp=sharing

82. Badal S, Her YF., et al. **Non-antibiotic effects of fluoroquinolones in mammalian cells.** The Journal of biological chemistry. 2015 Jul 23. [Epub ahead of print]

<http://www.ncbi.nlm.nih.gov/pubmed/26205818>

Endocrine organs and other organ involvement:

83. Kabbara WK, Ramadan WH., et al. **Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia.**

TherClin Risk Manag. 2015 Apr 22;11:639-47.

<http://www.ncbi.nlm.nih.gov/pubmed/25960658>

84. Chou HW, Wang JL, et al. **Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.**

Clin Infect Dis. 2013 Oct;57(7):971-80.

<http://www.ncbi.nlm.nih.gov/pubmed/23948133>

85. Sherrie L. Aspinall., et al. **Severe Dysglycemia with the Fluoroquinolones: A Class Effect? Clin Infect Dis. (2009) 49 (3): 402-408.**

<http://www.ncbi.nlm.nih.gov/pubmed/19545207>
<http://cid.oxfordjournals.org/content/49/3/402.full>

86. S Vallurupalli,* G Huesmann., et al. **Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia.** *Diabet Med.* 2008 Jul; 25(7): 856–859.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613252/>

87. Lu ZK1, Yuan J., et al. **Cardiac risks associated with antibiotics: azithromycin and levofloxacin.** *Expert Opin Drug Saf.* 2015 Feb;14(2):295-303
<http://www.ncbi.nlm.nih.gov/pubmed/25494485>

88. Rao GA1, Mann JR., et al, **Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.** *Ann Fam Med.* 2014 Mar-Apr;12(2):121-7
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Bennett+CL>

89. Pugi A, Longo., et al. **Cardiovascular and metabolic safety profiles of the fluoroquinolones.** *Expert Opin Drug Saf.* 2012 Jan;11(1):53-69.
<http://www.ncbi.nlm.nih.gov/pubmed/21958023>

90. Falagas ME, Rafailidis PI., et al. **Arrhythmias associated with fluoroquinolone therapy.** *International Journal of Antimicrobial Agents* Volume 29, Issue 4, April 2007, Pages 374–379
<http://www.ncbi.nlm.nih.gov/pubmed/17241772>

91. Iannini PB, Doddamani S., et al. **Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones.** *BMJ.* 2001 Jan 6;322(7277):46-7
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Risk+of+torsades+de+pointes+with+non-cardiac+drugs+Prolongation+of+QT+interval+is+probably+a+class+effect+of+fluoroquinolones>

92. Levine C, Trivedi A., et al. **Severe ductopenia and cholestasis from levofloxacin drug-induced liver injury: a case report and review.** *Semin Liver Dis.* 2014 May;34(2):246-51
<http://www.ncbi.nlm.nih.gov/pubmed/24879988>

93. Leise MD, Poterucha JJ., et al. **Drug-induced liver injury.** *Mayo Clinic Proceedings.* 2014 Jan;89(1):95-106
<http://www.ncbi.nlm.nih.gov/pubmed/24388027>

94. J. Michael Paterson, MSc, Muhammad M et al. **Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study.** *CMAJ.* 2012 Oct 2; 184(14): 1565–1570.

<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3470619/>

- 95.** Brennan Eadie, MD, PhD¹; Mahyar Etminan **Evidence Linking Some Fluoroquinolones to Uveitis Grows** JAMA Ophthalmology. 2014 JAMA Ophthalmol. 2015;133(1):81-84
- 96.** Etminan M, Forooghian F. et al. **Oral fluoroquinolones and the risk of retinal detachment.** JAMA. 2012 Apr 4;307(13):1414-9
<http://www.ncbi.nlm.nih.gov/pubmed/22474205>
- 97.** Mehlhorn AJ, Brown DA. **Safety concerns with fluoroquinolones.** Ann Pharmacother. 2007 Nov;41(11):1859-66. Epub 2007 Oct 2.
<http://www.ncbi.nlm.nih.gov/pubmed/17911203>
- 98.** Cooper JG, Harboe K., et al. **Ciprofloxacin interacts with thyroid replacement therapy.** BMJ. 2005 Apr 30;330(7498):1002.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=Ciprofloxacin+interacts+with+thyroid+replacement+therapy>.
- 99.** Yang SD¹, Bai ZL., et al. **Levofloxacin increases the effect of serum deprivation on anoikis of rat nucleus pulposus cells via Bax/Bcl-2/caspase-3 pathway.** Toxicol Mech Methods. 2014 Dec;24(9):688-96
<http://www.ncbi.nlm.nih.gov/pubmed/25224805>
- 100.** Bai ZL, Chen Q., et al. **Toxic Effects of Levofloxacin on Rat Annulus Fibrosus Cells: An In-vitro Study.** Med Sci Monit. 2014 Nov 8;20:2205-12.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237079/?report=classic>
- 101.** Wang L, Wu Y., et al. **Cytotoxic effects of the quinolone levofloxacin on rabbit meniscus cells.** J Appl Toxicol. 2014 Aug;34(8):870-7
<http://www.ncbi.nlm.nih.gov/pubmed/23813946>
- 102.** Khan M, Ortega LM¹., et al. **Crystal-induced acute kidney injury due to ciprofloxacin.** J Nephropathol. 2015 Jan;4(1):29-31. doi: 10.12860/jnp.2015.06. Epub 2015 Jan 1.
<http://www.ncbi.nlm.nih.gov/pubmed/25657983>
- 103.** Argirov M¹, Ricken G., et al. Acute interstitial nephritis associated with moxifloxacin use. Clin Ther. 2005 Aug;27(8):1260-3
<http://www.ncbi.nlm.nih.gov/pubmed/16199250>

Miscellaneous:

104.Linder JA, Huang ES., et al. **Fluoroquinolone prescribing in the United States: 1995 to 2002.** Am J Med. 2005 Mar;118(3):259-68.

[http://www.ncbi.nlm.nih.gov/pubmed/?](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fluoroquinolone+prescribing+in+the+United+States%3A+1995+to+2002)

[term=Fluoroquinolone+prescribing+in+the+United+States%3A+1995+to+2002](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fluoroquinolone+prescribing+in+the+United+States%3A+1995+to+2002)

105. Holleman F, Uijldert M., et al. **Productivity of authors in the field of diabetes: bibliographic analysis of trial publications.** BMJ. 2015 Jul 1;351:h2638.

[http://www.ncbi.nlm.nih.gov/pubmed/?](http://www.ncbi.nlm.nih.gov/pubmed/?term=Productivity+of+authors+in+the+field+of+diabetes%3A+bibliographic+analysis+of+trial+publications.+The+BMJ%2C+July+2015)

[term=Productivity+of+authors+in+the+field+of+diabetes](http://www.ncbi.nlm.nih.gov/pubmed/?term=Productivity+of+authors+in+the+field+of+diabetes%3A+bibliographic+analysis+of+trial+publications.+The+BMJ%2C+July+2015)

[%3A+bibliographic+analysis+of+trial+publications.+The+BMJ%2C+July+2015](http://www.ncbi.nlm.nih.gov/pubmed/?term=Productivity+of+authors+in+the+field+of+diabetes%3A+bibliographic+analysis+of+trial+publications.+The+BMJ%2C+July+2015)

106. **Concerns about industry dominance in diabetes research.**

<http://www.sciencedaily.com/releases/2015/07/150701214541.htm>

107. **Dear doctor letter Todd Plumb M.D. 2006.**

[https://attachment.fsbx.com/file_download.php?](https://attachment.fsbx.com/file_download.php?id=555395031193358&eid=ASvcPLIkVLFBc55rTFuAXaLrOs0E6kwwKQHDNwdYtCCmZ-IH7kOoEQiJ1rlza5qz9Rc&inline=1&ext=1438663227&hash=ASv8IA-496ZB5Apz)

[id=555395031193358&eid=ASvcPLIkVLFBc55rTFuAXaLrOs0E6kwwKQHDNwdYtCCmZ-IH7kOoEQiJ1rlza5qz9Rc&inline=1&ext=1438663227&hash=ASv8IA-496ZB5Apz](https://attachment.fsbx.com/file_download.php?id=555395031193358&eid=ASvcPLIkVLFBc55rTFuAXaLrOs0E6kwwKQHDNwdYtCCmZ-IH7kOoEQiJ1rlza5qz9Rc&inline=1&ext=1438663227&hash=ASv8IA-496ZB5Apz)

108. **Physicians' Desk Reference. 2015**

©2015 Miriam J. de Jonge, M.D.

This letter does NOT contain medical advice. Please consult your own doctor or healthcare provider to determine the best course of treatment for you. Readers should not make any changes in drugs, doses, or any other aspects of their medical treatment unless specifically directed to do so by their own doctors.